View Item 

Show simple item record

Meta‐analysis: IL ‐28 B genotype and sustained viral clearance in HCV genotype 1 patients
dc.contributor.authorRangnekar, A. S.en_US
dc.contributor.authorFontana, R. J.en_US
dc.date.accessioned2012-07-12T17:23:51Z
dc.date.available2013-09-03T15:38:27Zen_US
dc.date.issued2012-07en_US
dc.identifier.citationRangnekar, A. S.; Fontana, R. J. (2012). "Meta‐analysis: IL ‐28 B genotype and sustained viral clearance in HCV genotype 1 patients." Alimentary Pharmacology & Therapeutics (2): 104-114. <http://hdl.handle.net/2027.42/92057>en_US
dc.identifier.issn0269-2813en_US
dc.identifier.issn1365-2036en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/92057
dc.publisherWiley Periodicals, Inc.en_US
dc.titleMeta‐analysis: IL ‐28 B genotype and sustained viral clearance in HCV genotype 1 patientsen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbsecondlevelOtolaryngologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.identifier.pmid22612303en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/92057/1/apt5145.pdf
dc.identifier.doi10.1111/j.1365-2036.2012.05145.xen_US
dc.identifier.sourceAlimentary Pharmacology & Therapeuticsen_US
dc.identifier.citedreferenceSoriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV‐HIV International Panel. AIDS 2007; 21: 1073 – 89.en_US
dc.identifier.citedreferencePineda JA, Caruz A, Rivero A, et al. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2010; 51: 788 – 95.en_US
dc.identifier.citedreferenceRallon NI, Naggie S, Benito JM, et al. Association of a single nucleotide polymorphism near the interleukin‐28B gene with response to hepatitis C therapy in HIV/hepatitis C virus‐coinfected patients. AIDS 2010; 24: F23 – 9.en_US
dc.identifier.citedreferenceTorriani FJ, Rodriguez‐Torres M, Rockstroh JK, et al. Peginterferon Alfa‐2a plus ribavirin for chronic hepatitis C virus infection in HIV‐infected patients. N Engl J Med 2004; 351: 438 – 50.en_US
dc.identifier.citedreferenceBallesteros AL, Franco S, Fuster D, et al. Early HCV dynamics on Peg‐interferon and ribavirin in HIV/HCV co‐infection: indications for the investigation of new treatment approaches. AIDS 2004; 18: 59 – 66.en_US
dc.identifier.citedreferenceMuir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa‐2b and ribavirin for the treatment of chronic hepatitis C in blacks and non‐Hispanic whites. N Engl J Med 2004; 350: 2265 – 71.en_US
dc.identifier.citedreferenceCosta JM, Telehin D, Munteanu M, et al. HCV‐GenoFibrotest: a combination of viral, liver and genomic (IL28b, ITPA, UGT1A1) biomarkers for predicting treatment response in patients with chronic hepatitis C. Clin Res Hepatol Gastroenterol 2011; 35: 204 – 13.en_US
dc.identifier.citedreferenceO'Brien TR, Everhart JE, Morgan TR, et al. An IL28B genotype‐based clinical prediction model for treatment of chronic hepatitis C. PLoS One 2011; 6: e20904.en_US
dc.identifier.citedreferenceOchi H, Hayes CN, Abe H, et al. Toward the establishment of a prediction system for the personalized treatment of chronic hepatitis C. J Infect Dis 2012; 205: 204 – 10.en_US
dc.identifier.citedreferenceLadero JM, Martin EG, Fernandez C, et al. Predicting response to therapy in chronic hepatitis C: an approach combining IL28B gene polymorphisms and clinical data. J Gastroenterol Hepatol 2012; 27: 279 – 85.en_US
dc.identifier.citedreferenceChayama K, Hayes CN, Abe H, et al. IL28B but not itpa polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J Infect Dis 2011; 204: 84 – 93.en_US
dc.identifier.citedreferenceAkuta N, Suzuki F, Hirakawa M, et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010; 52: 421 – 9.en_US
dc.identifier.citedreferenceGellad ZF, Naggie S, Reed SD, et al. The cost‐effectiveness of a telaprevir‐inclusive regimen as initial therapy for genotype 1 hepatitis C infection in individuals with the CC IL‐28B polymorphism. Hepatology 2011; 54: 417A – 8A.en_US
dc.identifier.citedreferenceNeukam K, Camacho A, Lopez‐Biedma A, et al. Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)‐coinfected patients using HCV genotype, IL28B variations and HCV‐RNA load. J Hepatol 2012; 56: 788 – 94.en_US
dc.identifier.citedreferenceLabarga P, Barreiro P, Mira JA, et al. Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV‐hepatitis C virus‐coinfected patients with prior nonresponse or relapse. AIDS 2011; 25: 1131 – 3.en_US
dc.identifier.citedreferenceFattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S35 – 50.en_US
dc.identifier.citedreferenceManns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa‐2b plus ribavirin compared with interferon alfa‐2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958 – 65.en_US
dc.identifier.citedreferenceFried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa‐2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975 – 82.en_US
dc.identifier.citedreferenceHadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon‐alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346 – 55.en_US
dc.identifier.citedreferenceMorgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52: 833 – 44.en_US
dc.identifier.citedreferenceConjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131: 470 – 7.en_US
dc.identifier.citedreferenceGe D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment‐induced viral clearance. Nature 2009; 461: 399 – 401.en_US
dc.identifier.citedreferenceBalagopal A, Thomas DL, Thio CL. IL28B and the control of hepatitis C virus infection. Gastroenterology 2010; 139: 1865 – 76.en_US
dc.identifier.citedreferenceScott J, Holte S, Urban T, et al. IL28B genotype effects during early treatment with peginterferon and ribavirin in difficult‐to‐treat hepatitis C virus infection. J Infect Dis 2011; 204: 419 – 25.en_US
dc.identifier.citedreferenceHonda M, Sakai A, Yamashita T, et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139: 499 – 509.en_US
dc.identifier.citedreferenceThompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin‐28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120 – 9.en_US
dc.identifier.citedreferenceGhany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335 – 74.en_US
dc.identifier.citedreferenceFaruki H, Albrecht J, Morrison P, et al. Genotype frequencies of IL28B genetic polymorphisms rs12979860 and rs809917 in a large genetic database of various ethnic/racial origin individuals. Hepatology 2011; 54: 816A.en_US
dc.identifier.citedreferenceWhiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003; 3: 25.en_US
dc.identifier.citedreferenceWhiting PF, Rutjes AW, Westwood ME, et al. QUADAS‐2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011; 155: 529 – 36.en_US
dc.identifier.citedreferenceOwens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions – agency for healthcare research and quality and the effective health‐care program. J Clin Epidemiol 2010; 63: 513 – 23.en_US
dc.identifier.citedreferenceDarling JM, Aerssens J, Fanning G, et al. Quantitation of pretreatment serum interferon‐gamma‐inducible protein‐10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology 2011; 53: 14 – 22.en_US
dc.identifier.citedreferenceSuppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon‐alpha and ribavirin therapy. Nat Genet 2009; 41: 1100 – 4.en_US
dc.identifier.citedreferenceStattermayer AF, Stauber R, Hofer H, et al. Impact of IL28B genotype on the early and sustained virologic response in treatment‐naive patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 344 – 50.en_US
dc.identifier.citedreferenceBochud PY, Bibert S, Negro F, et al. IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. J Hepatol 2011; 55: 980 – 8.en_US
dc.identifier.citedreferenceFattovich G, Covolo L, Bibert S, et al. IL28B polymorphisms, IP‐10 and viral load predict virological response to therapy in chronic hepatitis C. Aliment Pharmacol Ther 2011; 33: 1162 – 72.en_US
dc.identifier.citedreferenceMontes‐Cano MA, Garcia‐Lozano JR, Abad‐Molina C, et al. Interleukin‐28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 2010; 52: 33 – 7.en_US
dc.identifier.citedreferenceAlestig E, Arnholm B, Eilard A, et al. Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection. BMC Infect Dis 2011; 11: 124.en_US
dc.identifier.citedreferenceLindh M, Lagging M, Arnholm B, et al. IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1. J Viral Hepat 2011; 18: e325 – 31.en_US
dc.identifier.citedreferenceMcCarthy JJ, Li JH, Thompson A, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138: 2307 – 14.en_US
dc.identifier.citedreferenceHayes CN, Kobayashi M, Akuta N, et al. HCV substitutions and IL28B polymorphisms on outcome of peg‐interferon plus ribavirin combination therapy. Gut 2011; 60: 261 – 7.en_US
dc.identifier.citedreferenceKurosaki M, Tanaka Y, Nishida N, et al. Pre‐treatment prediction of response to pegylated‐interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol 2011; 54: 439 – 48.en_US
dc.identifier.citedreferenceTanaka Y, Nishida N, Sugiyama M, et al. Genome‐wide association of IL28B with response to pegylated interferon‐alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105 – 9.en_US
dc.identifier.citedreferenceLin CY, Chen JY, Lin TN, et al. IL28B SNP rs12979860 is a critical predictor for on‐treatment and sustained virologic response in patients with hepatitis C virus genotype‐1 infection. PLoS One 2011; 6: e18322.en_US
dc.identifier.citedreferenceSinn DH, Kim YJ, Lee ST, et al. Association of a single nucleotide polymorphism near the interleukin‐28B gene with response to hepatitis C therapy in Asian patients. J Gastroenterol Hepatol 2011; 26: 1374 – 9.en_US
dc.identifier.citedreferenceHuang CF, Huang JF, Yang JF, et al. Interleukin‐28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin. J Hepatol 2012; 56: 34 – 40.en_US
dc.identifier.citedreferenceHayashi K, Katano Y, Honda T, et al. Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg‐interferon and ribavirin therapy. Liver Int 2011; 31: 1359 – 65.en_US
dc.identifier.citedreferenceAkuta N, Suzuki F, Hirakawa M, et al. Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy. Intervirology 2012; 55: 231 – 41.en_US
dc.identifier.citedreferenceAparicio E, Parera M, Franco S, et al. IL28B SNP rs8099917 is strongly associated with pegylated interferon‐alpha and ribavirin therapy treatment failure in HCV/HIV‐1 coinfected patients. PLoS One 2010; 5: e13771.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
apt5145.pdf
Size:
261.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.